Answer
Bevacizumab gamma binds all VEGF-A isoforms, preventing their interaction with VEGFR-1 and VEGFR-2 receptors on endothelial cells, thereby suppressing endothelial cell proliferation, new blood vessel formation and vascular permeability to block abnormal blood vessel growth at the back of the eye.
Sources for this answer
- Lytenava 25 mg/mL solution for injectionOutlook Therapeutics Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 4Document updated
Sources checked